Acting as your CMO, strategic and operational, tailored to your needs
To focus resources on tumors with the highest potential for PoC and rule out early costly clinical dead ends
F: +41 79 624 79 55
M: a.rinaldi@medexpansion.ch
My structured sequential analysis bridges cell-stage results and tomorrow’s clinical reality :
Years Experienced
Start-up interactions
Welcome to my Clinical Dev Blog, a repository for my LinkedIn posts, 1‑minute videos and slide carousels.
Here I share cutting-edge, experience‑based insights on oncology clinical development, practical ideas to help you de‑risk projects, speed up trials and reach phase 2 PoC faster
ADCs were designed to selectively kill biomarker-positive cancer cells, but real-world results are complex. Learn why early clinical analysis is key to balancing efficacy, biomarker
ADCs disrupt the “biomarker = efficacy” model in precision medicine. Learn why payload, linker, and biomarker thresholds shape tumor selection, Phase 2 strategy, and clinical
Oncology is shifting fast. Base your clinical strategy on predictive cell testing, not animal studies. Identify the right tumors early and avoid dead ends.
The biotome may impact response to immunotherapy. Could it become a new predictive biomarker in oncology? A look at recent scientific insights.
